Jonsson Comprehensive Cancer Center at the University of California at Los Angeles: Adding Ribociclib to Hormone Therapy Reduces the Risk of Breast Cancer Recurrence
March 21, 2024
March 21, 2024
LOS ANGELES, California, March 21 (TNSres) -- The Jonsson Comprehensive Cancer Center at the University of California at Los Angeles issued the following news:
A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investi . . .
A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investi . . .